Back to Search Start Over

Ramucirumab approved for gastric cancer.

Source :
Cancer discovery [Cancer Discov] 2014 Jul; Vol. 4 (7), pp. 752-3. Date of Electronic Publication: 2014 May 08.
Publication Year :
2014

Abstract

Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.<br /> (©2014 American Association for Cancer Research.)

Details

Language :
English
ISSN :
2159-8290
Volume :
4
Issue :
7
Database :
MEDLINE
Journal :
Cancer discovery
Publication Type :
Periodical
Accession number :
25002597
Full Text :
https://doi.org/10.1158/2159-8290.CD-NB2014-069